Jessicca Rege

Jessicca M. Rege, Ph.D. is the Chief Executive Officer of Sus Clinicals, Inc., a biotech accelerating cancer drug development through the Oncopig Cancer Model, an FDA-cleared, genetically engineered pig platform for preclinical testing. A pharmaceutical scientist with more than 15 years in oncology R&D and global medical affairs, she previously served as Chief Development Officer at Mural Oncology, where she helped lead the company's public offering, and as VP, Head of Clinical Development, Oncology at Alkermes. She holds a Ph.D. in pharmaceutical sciences with a focus on pharmacogenomics from Virginia Commonwealth University.